Intralesional interferon in the treatment of Peyronie's disease: a pilot study.
OBJECTIVE
To investigate the effect of intralesional interferon on patients with severe Peyronie's disease.


METHODS
Thirteen patients with Peyronie's disease and associated penile deformity of greater than 12 months' duration were selected. Characteristics of the plaque and the degree of deformity were measured objectively. Ten patients received 1.5 MU of alpha 2B-interferon intralesionally three times a week for 3 weeks. Three patients received similar volumes of intralesional saline.


RESULTS
Six of the 10 patients who received interferon reported the complete disappearance of pain on erection and an improvement in the penile deformity. Although the objective improvement in deformity was relatively small, with a mean improvement of 20 degrees, patients with a small plaque (< 4 cm) had a better response. All those receiving interferon had predictable but brief side-effects similar to the symptoms of influenza.


CONCLUSIONS
Intralesional interferon is safe and well tolerated and results in symptomatic and some objective improvement, especially in patients with smaller Peyronie's plaques.
Judge
I S
IS
Department of Urology, Sir Charles Gairdner Hospital, Perth, Western Australia.
Wisniewski
Z S
ZS
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000628:therapy*; D010865:Pilot Projects; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins